Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

Stopped early · Phase 2

Conditions studied: Atherosclerotic Coronary Vascular Disease

In brief

The study was designed to evaluate the use of ETT electrocardiogram (ECG) indices as biomarkers in the assessment of atherosclerotic coronary vascular disease (ASCVD).

Key facts

Study ID

NCT01562041

Run by

Novartis Pharmaceuticals

People needed

14

Starts

2012-03-09

Expected to finish

2014-01-02

Last updated by the study team

2021-06-18

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• History of stable coronary artery disease

You may not qualify if…

• Inability or unwillingness to participate in multiple exercise treadmill tests and/or any other requirements of this study as assessed by the Investigator.
• History of chronic atrial fibrillation.
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Novartis Investigative Site — Jacksonville, Florida, United States
• Novartis Investigative Site — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.